companiesCompany
IASO Biotherapeutics
aka 驯鹿生物, IASO Bio
IASO Bio developed eque-cel, the fully human BCMA CAR-T for myeloma approved in China in 2023 and partnered with Innovent.
Overview
Spun out of work at Tongji Hospital, Wuhan; equecabtagene autoleucel (Fucaso) approved June 2023; pipeline in CD19 and BCMA CAR-T for autoimmune disease and a CD19/BCMA dual CAR-T. Also holds FDA RMAT designation for eque-cel.
Headquarters
Nanjing / Shanghai, CN
Scorecard
All companies#145of 680 companies, score 15
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +4
1 approved, 0 in phase 3, 0 earlier, 1 targets, 4 registry studies. Formula on the scorecards page.
Type
cell therapy
Website
Founded
2017
Pages like this
not linked directly; found by shared links- PersonMichael Yu (Yu De-Chao)
Shares Equecabtagene autoleucel, Innovent Biologics and the tag china.
- CompanyGenFleet Therapeutics
Shares Innovent Biologics and the tag china.
- TrialORIENT-11
Shares Innovent Biologics and the tag china.
- TrialORIENT-16
Shares Innovent Biologics and the tag china.
- TrialORIENT-32
Shares Innovent Biologics and the tag china.
- ProductFulzerasib
Shares Innovent Biologics and the tag china.
- ProductInaticabtagene autoleucel
Shares CAR-T cell therapy and the tag china.
- InstitutionPeking University People's Hospital
Shares CAR-T cell therapy and the tag china.